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Remission of type 2 diabetes following bariatric surgery is well established but identifying 
patients who will go into remission is challenging.  
Purpose 
To perform a systematic review of currently available diabetes remission prediction models, 
compare their performance, and evaluate their applicability in clinical settings. 
Data sources 
A comprehensive systematic literature search of MEDLINE, MEDLINE In-Process & Other 
Non-Indexed Citations, EMBASE and Cochrane Central Register of Controlled Trials was 
undertaken. The search was restricted to studies published in the last 15 years and in the English 
language.  
Study selection and data extraction 
All studies developing or validating a prediction model for diabetes remission in adults after 
bariatric surgery were included. The search identified 4165 references of which 38 were included 
for data extraction. We identified 16 model development and 22 validation studies.  
Data synthesis 
Of the 16 model development studies, 11 developed scoring systems and 5 proposed logistic 
regression models. In model development studies, 10 models showed excellent discrimination 
with area under curve (AUC) ≥ 0.800. Two of these prediction models, ABCD and DiaRem, were 
widely externally validated in different populations, a variety of bariatric procedures, and for both 
short- and long-term diabetes remission. Newer prediction models showed excellent 
discrimination in test studies, but external validation was limited. 
Limitations and Conclusions 
Amongst the prediction models identified, the ABCD and DiaRem models were the most widely 
validated and showed acceptable to excellent discrimination. More studies validating newer 




Bariatric surgery is an established cost-effective treatment option in patients with type 2 diabetes. 
In addition to sustained weight loss, it is associated with significant improvements in glycaemic 
control, including achieving type 2 diabetes remission (1-3), and reduction in the risk of micro- 
and macro-vascular complications and mortality (4-6). The proportion of patients achieving 
diabetes remission following bariatric surgery varies between studies and is estimated to be 
between 30 and 70%. This proportion lessens with longer follow-up and with longer diabetes 
duration at the time of surgery (7-9). This observed variation in the remission prevalence may be 
attributed to differences in definitions of diabetes remission, the population studied, the type of 
bariatric surgery, and the duration of follow-up.  
Type 2 diabetes is one of the main indications for bariatric surgery in people with obesity (10), 
Given the variation in the rates of diabetes remission following bariatric surgery, a number of 
studies aiming to identify predictors of diabetes remission following bariatric surgery have been 
published (11-14). Variables associated with better beta cell function such as younger age, shorter 
diabetes duration, high c-peptide, lack of insulin treatment, and lower pre-operative HbA1c (15) 
and lower pre-operative body mass index (BMI) have been identified as predictors of type 2 
diabetes remission post-surgery.  
Considering the importance of predicting diabetes remission for individualising care and helping 
patients and health care professionals to make informed decisions, several scoring systems 
incorporating the above-mentioned variables to predict diabetes remission have been developed 
(16-18).  
Acknowledging the mounting literature in this area and the increasing use of bariatric surgery 
worldwide, there is a need to describe the available prediction models and assess their ability to 
predict diabetes remission in patients with type 2 diabetes undergoing bariatric surgery and their 
utility in clinical practice.  
Methods 
This systematic review followed the PRISMA guidelines (19). The protocol was registered on 
PROSPERO, registration number CRD42019124644. 
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Literature search and screening 
We searched MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations, EMBASE 
(OVID), and Cochrane Central Register of Controlled Trials (CENTRAL). An example of the 
search strategy used in EMBASE can be found in Supplementary Table 1. Key search terms were 
type 2 diabetes, remission, and bariatric surgery. The search term for prognostic/predictive models 
included prediction, prognosis, sensitivity, specificity, ROC (receiver operating characteristics) 
curve, AUC (area under the curve) with wild cards as well as other search terms as per published 
guidance (20). 
The search was limited to papers published in the English language and in the last 15 years, as the 
concept of diabetes remission was established and coined by the American Diabetes Association 
(ADA) in 2009. The final search was performed on 26th January 2019 and updated on 8th August 
2020 (Figure 1). EPPI-reviewer 4 software was used for compiling the references, first screening 
by title and abstract, second screening of full text, and collaborating among reviewers (21).  
Study selection 
First screening by title and abstract was performed by two reviewers (PS and SB) independently. 
Discrepancies were discussed to reach a consensus. We included clinical studies (observational or 
interventional studies) (Setting, S) involving adults with type 2 diabetes (Participants, P) who 
subsequently had bariatric/metabolic surgery (Interventions, I), and those that developed or 
validated a prediction model to predict diabetes remission (Outcome, O). Multiple definitions of 
diabetes remission were used, but we included only those using definitions of HbA1c of ≤6.5% 
(48mmol/mol) and off glucose lowering medication, with follow-up of at least a year.  
We excluded review articles, studies whose participants included children/adolescents or those 
with gastric cancer or gastric ulcer, studies where the intervention was other than 
bariatric/metabolic surgery, studies which had an outcome of diabetes remission defined as HbA1c 
>6.5% (48 mmol/mol), studies which had a follow-up period less than 12 months, and studies 
where the analysis was limited to identifying predictors. 
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Data extraction and analysis 
The data extraction template was drafted on Distiller SR software (22). Data were collected by PS 
and independently collected by second reviewers (JH, NJA and SB). We adapted the Critical 
Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARM) 
toolkit (23) to design the data collection domains; we gathered data on the country, data source, 
type of study, demographics of participants, type of bariatric procedure, length of follow-up, 
definition of diabetes remission, statistical method used for model development, and performance 
measures (Supplementary Table 3). We calculated the discrimination scores for models when this 
was not reported by the authors and where data to calculate them were available in the publication.  
Risk of Bias assessment 
We used a customised version of the Prediction model risk of Bias Assessment Tool (PROBAST) 
to assess risk of bias and applicability (24). The assessment was done under 4 domains for risk of 
bias – participants, predictors, outcomes and analysis – and 3 domains for applicability and 
generalizability – participants, predictors and outcomes. The participants domain covers bias in 
patient selection and study design, the predictors domain is related to definition of predictors 
included in the prediction model, the outcome domain covers definition and measurement of the 
outcome, and the analysis domain relates to statistical analysis, handling missing data and 
overfitting (24) (Supplementary table 4). 
Statistical analysis 
A prediction model has three main phases: model development (preferably with internal 
validation), external validation, and investigation of clinical impact (25). Model development and 
validation involves identifying predictors, selecting the important predictors by regression 
analysis/modelling, proposing a model by assigning relative weights to the individual predictors 
included, conducting internal validation, and validating in an external cohort to avoid overfitting 
(26). In this review, we classed the studies which developed and internally validated a prediction 
model as model development studies, and studies which externally validated prediction models in 
a new cohort as validation studies. 
We explored these phases for the identified prediction models and assessed the performance (26, 
27). We assessed the performance of the models based on discrimination, defined as the ability to 
distinguish between those who will and who will not achieve the outcome of interest, and 
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calibration, defined as the ratio of those expected to have a desired outcome to those observed to 
achieve the outcome. 
For prediction models presented as a scoring system, the sensitivity and specificity will vary 
depending on different cut points. Therefore, we chose to assess discrimination using area under 
the receiver operating characteristic curve (AUC), which covers all the sensitivity and specificity 
values at different cut points (28) and allows comparison of the prediction models. AUC of 0.5 
signifies no ability to discriminate. For our study, we followed the categorisations used by Zhang 
et al, defining 0.501–0.699 as poor discrimination, 0.700–0.799 as acceptable discrimination, 
0.800–0.899 as excellent discrimination and 0.900–1 as outstanding (29). For studies which did 
not report AUC, where possible we calculated discrimination using published tables providing 
information on the participants, their score, and their outcome in terms of remission and non-
remission. We used Stata for the analysis, generating AUC graphs and values (with 95% 
confidence interval). Calibration was estimated by calculating the expected number (E) who 
should experience diabetes remission as reported in the model/score development paper and 
obtaining the observed number (O) from the tables providing information on score and outcome. 
This information was then used to calculate expected / observed (E/O) ratio (30). E/O ratio of 1 
represents perfect calibration, <1 represents underestimation of the events and >1 represents 
overestimation (30). 
As our search yielded studies with significant heterogeneity, we undertook three separate random 
effect meta-analyses of studies based on i) their duration of follow-up, ii) the HbA1c cut-offs used 
to define remission, and iii) the type of bariatric surgery (Figure 2 a-f). We excluded studies from 
analysis where AUC was not known or could not be estimated with 95% confidence interval. 
Our first meta-analysis was based on follow- up duration; studies were grouped into those with 
follow-up of 1 year and those with more than 1 year. In studies where diabetes remission was 
defined using two HbA1c cut-off values (e.g. 6.0% (42mmol/mol) and 6.5% (48mmol/mol)), we 
included the AUC for the higher cut-off only to avoid duplication of data sources. 
The second meta-analysis was based on HbA1c cut-offs and studies were grouped into those with 
HbA1c cut-offs of 6.5% (48mmol/mol) and 6% (42mmol/mol). In studies where diabetes 




The third meta-analysis was based on type of surgery; studies were grouped into gastric bypass 
(RYGB) or sleeve gastrectomy (SG) groups. We excluded studies in which the discrimination 
score was not available for specific interventions separately. Similar to the previous two meta-
analyses, we included the AUC for the higher HbA1c cut-off and longer follow-up duration where 
AUC was available for more than one HbA1c cut-off or length of follow-up. 
Results 
Following the initial search, we retrieved 5825 papers. After removing 1660 duplicates, 4165 
publications were identified for title and abstract screening. 91 publications were identified as 
eligible for full text screening. 44 were excluded as these were conference papers or posters with 
limited information, especially on methods and risk of bias. The remaining 47 published articles 
were screened by full text; 9 were excluded after screening the full text (reasons outlined in 
Supplementary Table 2). The remaining 38 published articles were retained for data extraction. 
Study characteristics  
Of the 38 studies included in this review, 16 focused on model development (Tables 1 and 2), and 
22 focused on external validation (Table 3). External validation studies were defined as studies 
validating a pre-defined prediction model in a different population or time period from the 
population/time period used to develop the model. 
Model development studies 
11 of the 16 model development studies produced scoring systems while the other five were 
logistic regression prediction models. The scoring systems were ABCD (Lee et al) from Taiwan 
in 2013 (16); Robert et al from France in 2013 (31); DiaRem (Still et al) from the USA in 2014 
(17, 32); Diabetes Remission Score (DRS, Ugale et al) from India in 2014 (33); Individualised 
Metabolic Score (IMS, Aminian et al) from the USA in 2017 (18); Advanced DiaRem (Ad-
DiaRem, Aron-Wisnewsky et al) from France in 2017 (34); DiaBetter (Pucci et al) from the UK 
in 2017 (35); DiaRem2 (Still et al) in 2018 (36), an updated version of the pre-existing DiaRem 
model developed by the same group; 5y-DR (Debedat et al) from France in 2018 (37); Metabolic 
Surgery Diabetes remission (MDR score, Mei Ching Moh et al) from Japan in 2020 (38); and 
Umemura et al 2020 from Singapore (39). The five logistic regression models were Hayes et al 
from New Zealand in 2011 (40); Dixon et al from Taiwan in 2013 (13); Ramos-Levi et al from 
Spain in 2014 (41); Cotillard et al from France in 2015 (42); and Stallard et al from Canada in 




Out of 16 studies, 14 studies used retrospective data and two used prospective data (13, 40). Eight 
studies included participants who had undergone RYGB (13, 16, 17, 34, 36, 37, 40, 42), two 
studies included participants who had SG (33, 39), and the remaining studies included more than 
one type of bariatric surgical procedure (18, 31, 35, 38, 41, 43). Study sample size ranged from 46 
to 690 participants, with a female preponderance except in two studies, DRS (Ugale et al) (33) 
and Umemura et al (39), which had higher male representation. The mean age of participants 
ranged between 36.5 years and 57.6 years, and mean BMI from 23.4 (33) to 49.7 kg/m2. Diabetes 
duration was available for all studies except Umemura et al (33). Mean diabetes duration ranged 
from 2.1 years in Lee et al (ABCD model) (16) to 9.9 years in Ugale et al (DRS model) (33). Pre-
operative HbA1c ranged from 6.8% (51mmol/mol) in Still et al (DiaRem score) (17) to 9.1% 
(76mmol/mol) in the Dixon et al study (13). 
Follow-up duration 
The median follow-up range was 1-5 years. The majority of the studies reported remission rates 
at one year. Three studies reported longer follow-up: 2 years in DiaBetter (Pucci et al) (35) and 5 
years in IMS (Aminian et al) (18) and 5y-DR (Debedat et al) (37).  
Outcome definition 
Different definitions for diabetes remission were noted with some focusing on complete diabetes 
remission (defined as HbA1c <6.0% (42mmol/mol) and no anti-diabetic medication for at least 12 
months) (13, 16, 31, 37) and others combining complete and partial diabetes remission (defined 
as <6.5% (48mmol/mol) and off medications for 12 months) (17, 18, 34, 38, 39). DiaRem2 (36) 
and Stallard et al (43) defined diabetes remission as a HbA1c of less than 5.7% (39mmol/mol) and 
≤5.9% (41mmol/mol) off anti-diabetic medications at 12 months, respectively. 
Method/analysis and presentation 
Predictors in the models varied and included age, baseline BMI, C-peptide, diabetes duration, 
HbA1c, insulin use, glucose lowering medications, sex, micro- and macro-vascular complications. 
5y-DR (37) included post-operative variables as predictors in the prediction model. The number 
of predictors ranged from 2 (40) to 10 (42). Five prediction models proposed a logistic regression 
model; the Dixon et al (13) and Hayes et al (40) models gave a logarithmic equation; while Ramos-
Levi et al (41), Cotillard et al (42) and Stallard et al (43) defined the predictors to be included in 
the prediction model, but gave no equation in their publication.  
9 
 
The method for deriving the scoring system varied among the 11 models. DiaRem (17) and 
DiaRem2 (36) reported hazard ratios using Cox regression and odds ratios of the final logistic 
models, respectively, to create a scoring system. Umemura et al (39) used a weighing algorithm 
and gave an odds ratio. IMS (18) used a nomogram and benchmarks selected by an expert panel. 
Ad-Diarem (34) and 5yDR (37) used machine learning; Ad-Diarem used a sparse support vector 
machine and formulated a linear integer programming task, and 5y-DR used a fully corrective 
binning approach to assign intervals and weight for each variable. MDR (38) used quartile and 
tertile cut-offs to obtain the weighting of each of the predictors in the scoring system. ABCD (16), 
Robert et al (31), DRS (33) and DiaBetter (35) offered no information on how the weighting for 
individual predictors was decided. 
Performance 
To represent the model performance, Ad-Diarem (34), Dixon et al (13), Robert et al (31), Ramos-
Levi et al (41), Stallard et al (43), DiaBetter (35), DiaRem2 (36), 5y-DR (37) and MDR (38) 
presented AUC. We calculated the AUC for ABCD (16), DiaRem (17) and Umemura et al (39) 
(Supplement materials 7). No AUC or performance was reported for DRS (33), IMS (18), Hayes 
et al (40) or Cotillard et al (42), and data in the publications were insufficient to calculate these. 
Out of 12 prediction models for which AUC was available, ten prediction models [Dixon et al 
(13), Ramos-Levi et al (41) and Stallard.et.al (43), DiaRem (17), Robert et al (31), Ad-Diarem 
(34), DiaBetter (35), DiaRem2 (36), 5y-DR (37), and Umemura et al (39)] had excellent 
discrimination (0.80 to 0.89) and two [ABCD (16) and MDR (38)] had acceptable discrimination 
(0.70-0.79), irrespective of diabetes remission definition (Table 1). 
Risk of bias Assessment 
The studies developing DiaRem (17) and Ad-DiaRem (34) were found to have low risk of bias 
and Dixon et al (13) was of unclear risk. The remaining model development studies had high risk 
of bias, mainly due to deficiencies in the analysis domain. However, the applicability in practice 
was of low risk in all model development studies (Supplementary Table 5). 
Validation studies 
We identified 22 studies externally validating the prediction models (44-65). Study characteristics 
are summarised in Table 3. Of the 22 external validation studies, nine validated the ABCD score, 





19 studies used retrospective data (44-48, 51, 52, 54-65), and three collected the data prospectively 
(49, 50, 53). The sample size ranged from 53 (53) to 2190 (61), and mean age ranged from 35.7 
(45) to 51.0 years (51, 52, 65). All studies had a female predominance except one (54). Mean BMI 
ranged from 26.9 kg/m2 (46) to 52.1 kg/m2 (50). Median diabetes duration ranged from 1 year (63) 
to 9.6 years (54), and mean pre-surgery HbA1c ranged from 7.2 (55mmol/mol) (60) to 9.1% 
(76mmol/mol) (46). 
Eight studies included participants who underwent RYGB (47, 48, 50-52, 57, 58, 62), five 
included participants who underwent SG (44, 54-56, 64), and the remaining nine included a range 
of surgery types (45, 46, 49, 53, 59-61, 63, 65).(Table 3). 
Follow-up duration 
One study had a follow-up period of 10 years (50), six studies had a follow-up period of 5 years 
(45, 49, 58, 59, 61, 64), one had 3 years’ follow-up (62), and the remaining studies had follow-
up of 1 year. 
Outcome definition 
To define diabetes remission, the HbA1c cut-off was taken as 5.7% (39mmol/mol) in two studies 
(51, 65); 6.0% (42mmol/mol) in 13 studies (44-49, 52, 54, 55, 58, 62, 64); and the remaining 
studies defined diabetes remission as HbA1c ≤6.5% (48mmol/mol). 
Performance  
Although 16 models were identified in model development studies, few of these were externally 
validated in more than one external cohort, and those that are predominantly scoring systems. 
Direct comparison of the models was seen in only six studies (48, 55, 57, 59, 61, 62). 
We have presented the assessment of validation studies based on the prediction models validated. 
As ABCD and DiaRem scores were validated most frequently, we have presented these studies 
first followed by the remainder of the prediction models externally validated. 
ABCD score 
In the original model development paper, the authors also reported an external validation in a new 
cohort (16). We calculated the AUC to be 0.79 (95% CI 0.73-0.86) (acceptable discrimination) 
(Table 1 and Figure 2) and calibration (E/O) as 1.01 in the external cohort. In a subsequent study, 
ABCD score cut-off values for each variable were modified (44). In this cohort, we calculated 
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AUC as 0.77 (0.68-0.87) and 0.79 (0.69-0.90) for complete and partial diabetes remission, 
respectively (44). Calibration was not available.  
The ABCD score with the new cut-offs (44) has been externally validated in 13 studies (45, 46, 
48, 49, 53-59, 62, 64). Out of these 13 validation studies, five looked at long-term diabetes 
remission at 3-5 years (45, 49, 59, 62, 64) and the remaining eight at 1 year. One study found poor 
discrimination (53) while others found the discrimination to be acceptable to excellent depending 
on the type of surgery and follow-up duration. Model development studies for MDR (38) and 
Umemura et al (39) also validated ABCD in their cohort and found the performance to be poor 
and excellent, respectively.  
It was difficult to ascertain the calibration score as it was not widely available, and when available, 
the results were inconsistent. Calibration was only mentioned in two studies (55, 62) and found to 
be overestimating by 13% (55) and 12% (62) for diabetes remission at 1 year and underestimating 
by 15% (62) at 3 years. 
ABCD meta-analysis 
For ABCD, meta-analysis of the results from multiple studies showed acceptable discrimination 
with AUC of 0.79 (95% CI 0.76-0.82) for 1-year follow-up and 0.80 (0.74-0.86) for longer-term 
follow-up (Figure 2a). 
At the different HbA1c cut-offs, discrimination was excellent with an AUC of 0.81 (95% CI 0.79-
0.83) for a HbA1c cut-off of 6.0% (42mmol/mol), and acceptable at 0.78 (0.74-0.81) for a HbA1c 
cut-off of 6.5% (48mmol/mol) (Figure 2b). 
For RYGB, meta-analysis showed excellent discrimination for ABCD with an AUC of 0.82 (95% 
CI 0.80-0.85), while for SG, discrimination was acceptable with AUC of 0.79 (0.76- 0.82) (Figure 
2c). 
DiaRem score  
The DiaRem score has been externally validated in 11 studies (47, 48, 51, 52, 55, 57, 60-62, 65, 
66) (Table 1 and Figure 2). Three studies looked at long term (>1 year) (61, 62, 66) diabetes 
remission and the remaining focussed on remission at 1 year. 
Five external validation studies found excellent discrimination (47, 50, 55, 57, 60), five found 
acceptable (48, 51, 61, 62, 65) and one found poor discrimination (52).  
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Calibration was presented in two studies (55, 62). We were able to calculate the E/O ratio for a 
further six studies: DiaRem underestimated the probability of diabetes remission in the Ahuja et 
al (57) (E/O ratio 0.67) and the Mahaffey et al studies (50) (E/O 0.63 at 2 years and 0.71 at 10 
years). It overestimated the probability of diabetes remission in the other four studies (47, 48, 51, 
52) with E/O ratios of 1.31, 1.71, 1.14, 1.25 in Honarmand et al (51), Lee et al (48), Sampaio-
Neto et al (47) and Tharakan et al (52), respectively. Calibration was inconsistent across the 
studies. 
The model development studies Ad-DiaRem (34), DiaBetter (35), DiaRem2 (36) and 5y-DR 
(37) validated DiaRem in their cohorts and found excellent discrimination, while Stallard et al 
(43) found good discrimination. 
DiaRem meta-analysis 
In meta-analysis, discrimination for DiaRem was AUC 0.78 (0.75-0.81) for short-term and 0.83 
(0.80-0.86) for longer-term follow-up (Figure 2b). 
At HbA1c cut-offs of 6.0% (42mmol/mol) and 6.5% (48mmol/mol), the AUCs were 0.77 (0.74-
0.80) and 0.81 (0.78-0.84), respectively (Figure 2d). 
For RYGB, meta-analysis showed acceptable discrimination for DiaRem with AUC of 0.78 (0.74-
0.82). No meta-analysis was performed for SG as there was only one study identified validating 
DiaRem in a SG cohort (Figure 2f). 
Performance of other prediction models 
The discrimination scores for other prediction model are summarised in Table 1. The IMS score 
was externally validated by three validation studies (55, 59, 63) and one Umemura et al model 
development study (39). Discrimination was found to be excellent in Shen et al, acceptable in the 
RYGB cohort of Chen et al (59) and in Park et al (63), but poor in the SG cohort of Chen et al 
(59) and Umemura et al (39).  
Ad-Diarem (34) was externally validated in three validation studies (55, 61, 62), and 5Y-DR 
model development study (37). The Kam et al study (62) found acceptable performance while the 
other three found excellent performance. 
DiaBetter (35), Dixon et al(13) and Ramos-Levi et al (41) were noted to have excellent 
discrimination (55), and DRS (33) had good performance in one external validation study (57). 
The Robert et al (31) and Hayes et al (40) prediction models performed poorly in one external 
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validation with an AUC <0.70 (55). No external validation studies are available for DiaRem2 (36), 
Stallard et al (43), Cotillard et al (42), 5y-DR (37), MDR (38) or Umemura et al (39).  
Calibration in an external validation study for Ad-Diarem, DiaBetter, Dixon et al, and Ramos-
Levi et al found the models to be overestimating with predicted (or expected) to observed ratios 
of 1.06, 1.05, 1.13 and 1.12, respectively (55). Hayes et al and Robert et al were noted to be 
overestimating by 23-30% with predicted to observed ratios of 1.23 and 1.30, respectively (55). 
Risk of bias assessment 
Guerron et al (65) had low risk of bias, three studies (45, 50, 53) were classified as high risk of 
bias as a result of the analysis domain, and the remaining external validation studies had unclear 
risk of bias (Supplementary Table 6). We rated risk of bias in the analysis domain as unclear if 
either information on missing data was not reported or was not included in the analysis, or model 
performance was not reported; if neither was reported, we rated the domain as high risk of bias. 
However, no concerns were raised in terms of applicability, with all studies rated as low risk. 
Ideally, a sensitivity analysis restricted to low risk of bias studies should be performed. In our 
review, only one external validation study – validating the DiaRem model – was rated as low risk 
of bias (65); results of the meta-analysed studies for DiaRem were consistent with the findings of 
this study. 
Discussion 
In this systematic review, we have identified currently available models for predicting diabetes 
remission following bariatric surgery. We assessed and compared the performance of these models 
and evaluated their applicability in clinical settings. The most externally validated models in our 
review were ABCD and DiaRem. Although the ABCD and DiaRem models were primarily 
developed for predicting diabetes remission at 1-year follow-up, they have been validated in 
studies predicting long term diabetes remission. The AUC estimate for DiaRem for long-term 
diabetes remission and diabetes remission defined with a HbA1c cut-off of 6.5% (48mmol/mol) 
was higher than for ABCD. The AUC for ABCD for predicting short-term remission and diabetes 
remission defined by a HbA1c cut-off of 6.0% (42mmol/mol), was higher than that for DiaRem. 
Specifically for patients who underwent RYGB, AUC was higher in ABCD than for DiaRem. 
However, in all instances, confidence intervals overlapped. 
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Due to the lack of discrimination (AUC) score with 95% CI, we were not able to include in our 
meta-analysis three studies (34, 37, 43) conducted on patients who underwent RYGB and 
validating DiaRem that otherwise showed excellent performance. Furthermore, many studies 
validating ABCD were conducted by the same authors who developed the ABCD model and 
included similar patient cohorts to the derivation population, raising the possibility of bias based 
on population selection. It was therefore not possible to determine whether one model was better 
than other. 
Remission of diabetes is an important outcome for patients considering bariatric surgery. A project 
by Diabetes UK, led by patients with type 2 diabetes and their carers, identified diabetes cure or 
reversal as a top research priority (67). With the increasing number of patients with obesity and 
type 2 diabetes now being offered bariatric surgery, it is important to identify those who are more 
likely to achieve remission. This will enable patients and health care professionals to make 
informed choices when considering different treatment options. However, given the wide choice 
of prediction models currently available, it is difficult to identify the ones that best predict 
remission and are easy to use in routine clinical practice. 
The models identified in our review had certain common characteristics in relation to the 
predictors included and the duration of follow-up, which for most studies was 12 months. On the 
other hand, there was considerable heterogeneity in the definition of diabetes remission, cohort 
size and populations studied, including types of bariatric surgery, thereby adding to the difficulty 
in comparing these models. We found significant variation in the threshold for HbA1c used to 
define diabetes remission, with cut-offs ranging from 5.7 to 6.5% (39 to 48mmol/mol), and with 
some studies using a combination of partial and complete remission. However, in this review, we 
found that the definition did not affect the performance of the prediction models significantly. 
Duration of diabetes remission is an important consideration when assessing the benefits of 
bariatric surgery in patients with type 2 diabetes. In our review, we observed that 13 out of 16 
model development studies were designed with the aim of predicting diabetes remission at 1 year 
thus underscoring the need for longer follow-up of cohorts (18). The rate of diabetes remission 
has been inversely associated with diabetes duration and has been noted to be greatest in patients 
with shorter diabetes duration (12, 68). Moreover, diabetes remission is highest during the first 
year following the intervention and declines over subsequent years and with longer follow-up (7-
9). The prospective SOS study, with follow-up of over 18 years, showed the incidence of diabetes 
remission was 72.3% at 2 years, 38.1% at 10 years and 30.4% at 15 years (69). A randomised 
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controlled trial with 5 years’ follow-up found diabetes relapse in 53% of patients in the RYGB 
group and 37% in the biliopancreatic diversion group among patients who achieved diabetes 
remission at 2 years’ follow-up (9). Similar results were reported in a retrospective multisite study 
from the US with 5 years’ follow-up (70). These findings suggest that diabetes may relapse over 
time and that in a high proportion of patients, remission of diabetes may only be achieved for a 
short term. Despite this, short-term diabetes remission may offer huge clinical and financial 
benefits to patients and healthcare systems. Beside the benefit of reduction in the incidence of 
micro- and macro-vascular diabetes-related complications, short-term diabetes remission, through 
freedom from diabetes medications and reduced need for monitoring, may motivate patients to 
maintain weight loss and enhance their quality of life. 
Future studies should therefore include a uniform and agreed definition of diabetes remission and 
a longer follow-up period to determine the effects of bariatric surgery on long-term diabetes 
remission. This is particularly important when considering the cost-effectiveness of bariatric 
surgery. 
The outcomes of bariatric surgery such as weight loss and long-term metabolic benefit varies with 
the type of bariatric procedure (5, 71, 72). A network meta-analysis showed that the probability 
of achieving diabetes remission was greatest in mini-gastric bypass (91.2%), followed by 
biliopancreatic diversion without duodenal switch (87.3%), laparoscopic sleeve gastrectomy 
(61.4%), Roux-en-Y gastric bypass (59.3%), gastric banding (29.6%), and then great curvature 
plication (18.6%) (72). Despite this, none of the prediction models included the type of surgery as 
a predictor. However, when we analysed the performance of prediction models in RYGB and SG 
separately, we found no major differences between the two procedures. With many new bariatric 
procedures becoming available, there is a need to develop and validate the models across the 
various bariatric procedures.  
The indication for bariatric surgery in patients with BMI <35 kg/m2 is contentious and currently, 
none of the guidelines recommend bariatric surgery in non-obese individuals. In a recent 
systematic review and meta-analysis Ji et al evaluated 12 studies examining the impact of bariatric 
surgery in patients with type 2 diabetes and BMI <30 kg/m2 over a follow-up period ranging from 
6 months to 3 years (73) . They found a 1.58%(~16mmol/mol) reduction in HbA1c at 2 years 
using a random effects model (73). However, other studies comparing the impact of bariatric 
surgery in populations with and without obesity observed that surgery in a population without 
obesity is a less effective tool for diabetes management (74). We found two studies -a  model 
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development study by Ugale et al (33) and the validation study Lee et al (46) that focused on 
cohorts with mean BMI ≤30 kg/m2; Ugale et al did not provide model discrimination, and Lee et 
al found acceptable discrimination in this normal weight population. Based on available data, it is 
difficult to assess the performance of prediction models in those with low BMI. The impact of 
BMI on the performance of the prediction models is important and requires further study. 
Susceptibility to type 2 diabetes is known to vary among people of different ethnicities, and it is 
likely that these differences may extend to remission of diabetes following bariatric surgery. In 
the studies included in our review, the test cohort for DiaRem was 98% Caucasian, while for 
ABCD, the participants were from 5 Asian clinics. We identified one validation study by Wood 
et al validating the DiaRem score in a White and Hispanic population that noted an AUC of 0.84 
(0.80-0.88) and 0.79 (0.71-0.86) in White and Hispanic patients, respectively (60). A meta-
analysis including 14 studies showed greater weight loss in Caucasians compared to African 
Americans, but no difference was noted in the outcome of diabetes remission between these two 
ethnic groups (75, 76). None of the prediction models identified ethnicity as a predictor and data 
on direct comparisons between ethnic groups was limited to the above-mentioned studies. We 
were therefore unable to explore any possible differences between ethnicity and incidence of 
diabetes remission post-bariatric surgery. 
Five of the models, including two scoring systems, ABCD (16) and DRS (33), and three logistic 
regression models, Dixon et al (13), Ramos-Levi et al (41) and Cotillard et al (42), included C-
peptide levels (13, 16, 33, 41, 42) as one of the predictors. C-peptide can be measured as urinary 
C-peptide, urinary C-peptide creatinine ratio or venous blood C-peptide levels measured as 
random, fasting, or stimulated state (glucagon stimulation test, mixed meal tolerance test) (77). 
These factors may pose difficulties in standardisation and can present as a limitation when using 
certain scoring systems that have C-peptide as one of the predictors. Moreover, C-peptide is not 
measured routinely in the diagnosis or management of type 2 diabetes in most clinical settings. 
Prediction models using C-peptide, therefore, cannot be widely used by primary care physicians 
or in the early stages of weight management consultation. Models such as DiaRem and Ad-
DiaRem that focus predominantly on routinely measured clinical parameters may therefore have 
greater applicability across a wider range of clinical settings. If C-peptide is available, however, 
ABCD (16) is a reliable prediction model with a similar predictive performance, and has the 
advantage of being validated in different bariatric procedures and for long-term diabetes remission 
(49, 59, 62). 5y- DR (37) included post-operative number of glucose-lowering medications, fasting 
capillary blood glucose, weight loss and 1-year remission to predict long-term diabetes remission. 
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Post-operative parameters will not be available in the clinical consultation setting for bariatric 
surgery and hence use of this prediction model is limited.  
Treatment with insulin has been used in many models as a predictor. Patient preference for non-
insulin treatments and therapeutic inertia are recognized causes for delay in treatment with insulin 
(78). In instances where insulin treatment is delayed, treatment with insulin as a predictor can 
overestimate the chances of remission. Conversely, if insulin is initiated early, it may 
underestimate the possibility of diabetes remission.  
The inconsistency in calibration scores with existing models either overestimating or 
underestimating the observed remission rates suggests that there are other variables that could 
influence remission. The utility of the prediction models largely depends on the clinical setting 
and resources available. The choice of a model used to predict remission must therefore be tailored 
to these factors. 
Strengths and Limitations 
We believe our study is the first systematic review summarising prediction model performance 
for diabetes remission in patients undergoing bariatric surgery. We calculated the discrimination 
score (AUC) for the studies where data were available and where AUC was not reported by the 
authors themselves.  
While the robust search strategy used in this review is a strength of our study, there are certain 
limitations: we restricted our search to articles published in English and published in the last 15 
years. We were also unable to contact the authors for further information regarding the 
performance of prediction models, where pertinent information was not available. It is possible 
that some relevant articles were not included in the review and meta-analysis. However, not many 
prediction models were available before our search date and the likely impact of this on our 
findings would be minimal. 
While the key messages were consistent, a large proportion of the studies were conducted in 
small cohorts of patients with short duration of follow-up. The majority of external validation 
studies used routinely collected data; consequently, follow-up data was not available for all 
patients who underwent bariatric surgery. While the studies had predefined inclusion and 
exclusion criteria for participants, with complete data at 1 year of follow-up for those included, 
there remains a possibility of selection bias due to lack on information on patients lost to follow-
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up in the routinely collected source data. Validation studies in large cohorts with longer follow-
up are therefore needed to overcome these limitations. 
Conclusions 
This systematic review identified 16 prediction models, with DiaRem (17) and ABCD (16) as 
the two most widely validated models to predict diabetes remission following bariatric surgery. 
Newer models published in the last three to four years showed promising results in test cohorts 
but there are a limited number of external validation studies. More external validation studies are 
needed for assessing the performance and clinical applicability of the new prediction models. 
Future studies should also examine these models in real world clinical settings to assess the 
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Table 1: Model development studies with their predictors 
Prediction Model Predictors included Discrimination in study 
development 
Discrimination in external validation study 
ABCD; Lee et al 2013 
(16) 
Age, BMI, C-peptide, and diabetes duration 0.792 (0.728-0.856)* Figure 2 a, c,and e 
DiaRem; Still et al 2014 
(17) 
Age, HbA1c, diabetes medication other than metformin, and 
insulin use 
0.840 (0.795-0.886)* Figure 2 b, d and f 
Robert et.al 2013 (31) BMI, diabetes duration, HbA1c, fasting glucose, and 
diabetes medication 
0.950 (0.838-0.992) Shen et al- 0.681 ± 0.056 
DRS; Ugale S 2014 (33) Age, baseline BMI, diabetes duration, microvascular 
complications, macrovascular complication, insulin use and 
stimulated C-peptides 
NA Ahuja et al- 0.732 (0.633-0.83)* 
Ad-DiaRem; Aron-
Wisnewsky et.al 2017 
(34) 
Age, HbA1c, insulin use, diabetes medication other than 
metformin, number of glucose-lowering agents, and diabetes 
duration 
0.911 Shen et al- 0.849 ± 0.039 
   Dicker 0.85 (0.76-0.93) 
   Kam et al@1 year 0.752 (0.688-0.808) 
   Kam et al @3 years 0.794 (0.715-0.860) 
   5y- DR  84% 
DiaBetter; Pucci et.al 
2017 (35) 
HbA1c, diabetes duration, and kind of diabetes medication 0.867 (0.817-0.916) Shen et al 0.826 ± 0.041 
   Kam et al @1 year 0.760 (0.697-0.815) 





IMS; Aminian et.al 2017 
(18) 
Number of diabetes medication, insulin use, diabetes 
duration, and HbA1c 
NA Shen et al 0.849±0.040 
   Park et al 0.76 (0.685-0.836)* 
   Chen et al 0.766 (0.716-0.817)* in GB 
   Chen et al 0.599 (0.501-0.697)* in SG 
   Umemura 0.516 (0.330-0.702)* 
DiaRem2; Still et al 2018 
(36) 
Age, HbA1c, diabetes medication other than metformin, and 
insulin use, diabetes duration 
0.876 NA 
5y- DR, 2018 (37) Pre-op factors- diabetes dur, no of medication, HbA1c 90% NA 
 Post-op factors- No of medication, fasting CBG, weight loss, 




(MDR), 2020 (38) 
Age, HOMA2-B, diabetes duration and HbA1c 0.79 (0.71- 0.88) NA 
Umemura et al 2020 (39) Insulin, diabetes duration 0.865 (0.775-0.954)* NA 
Hayes et.al 2011 (40) Insulin use and HbA1c NA 0.632 ± 0.059 
Dixon el.al 2013 (13) BMI and diabetes duration, c-peptide 0.90 (0.84-0.95) 0.800 ± 0.047 
Ramos-Levi et al 2014 
(41) 
Model1: age, sex, FG, diabetes duration, insulin 0.838 (0.725-0.951)  
 
Model2: age, sex, FG, diabetes duration, insulin, c-peptide 0.923 (0.852-0.996) 0.811 ± 0.047 
 
Model3: age, sex, FG, diabetes duration, insulin, % wt loss 0.923 (0.851-0.996)  
 
Model4: age, sex, FG, diabetes duration, insulin, % wt loss, 
c-peptide 
0.981 (0.951-1.000)  
Cotillard et al 2015 (42) Age, sex, BMI, fasting glycemia, HbA1c, hypertension, 
diabetes duration, insulin therapy, number of anti-diabetic 






Stallard et al 2016 (43) diabetes duration, FPG, use of non-insulin anti-diabetic 
medications and use of insulin. 
0.860 (0.763-0.957) NA 
* = calculated by authors of this systematic review. BMI = body mass index, HbA1c = glycosylated haemoglobin, HOMA2-B = Homeostasis 






Table 2: Study characteristics of model development studies 
Publication 
Reference 











   Age BMI 
Diabetes 
Duration 





ABCD; Lee et al 




 Taiwan 17 M:56 F     FU=1 year     
 Multi-centre R 36.5± 10.7 40.9 ± 8.9 2.1 ± 3.7 8.2± 1.8      
 2005- 2010 NR 44.5 ± 7.7 33.3 ±7.4 4.1 ± 4.5 8.5 ± 1.8      
DiaRem; Still et al 




 USA 184 M:506 F     FU=14 months     
 Multi-centre NI (n=438) 48.8± 10.3 49.5± 8.0 6.8± 1.2 NA      
 01/01/04 – 02/11 I (n=252) 53.6 ± 8.9 49.2 ± 8.8 8.2 ± 1.7 NA      
Robert et.al 2013 
(31) Retrospective N=46 45.3±1.6 49.5 ±1.22 3 (IQR 2.0-6.42) 7.44±0.24 
DR=62.8 % at 






 observation M:F=1:3      GB( 11)    
 France       SG(9)    
 2007- 2010           
DRS; Ugale S 2014 




 India 49 M:26 F     FU=1-2.5 years     













 France M 30%     FU=1 year     
 1999- 2014 R 46±10 48.1±7.4 3.5±3.8 7.0 ± 1.1      
  NR 53±9 45.4±7 11.1±7.6 8.4 ± 1.6      
DiaBetter; Pucci 




 UK RYGB (107) 51.6±8 43.1 ± 6.3 5.6 ± 5.1 4.7 ± 5.4 FU=2 years SG    
 Single SG (103) 49.7±8.8 48.2 ± 7.8 7.8 ± 1.5 7.3 ± 1.4      
 01/01/08 – 12/15           
IMS; Aminian et.al 




 USA F=451 (68%)     FU=5 years SG    
 Single           
 2004- 2011           
DiaRem2; Still et al 
2018 (36) 




 USA F=69%     FU=1 year     
 Single           
 2009- 2015           











    94 (53.7) @ 5     
       
FU=5.1 ± 
0.7year 
    
Metabolic Surgery 
Diabetes remission 
(MDR); Moh 2020 
(38) 




 Singapore      FU=1 year SG    
 2007-2018           
Umemura et al 
2020 (39) 




 Single F=22 (44.9%)     FU=1 year     
 2008- 2018           
 Japan           
Hayes et.al 2011 
(40) 




 Single 45 M:82 F     FU=1 year     
 01/11/97 – 05/07           
Dixon el.al 2013 
(13) 




 Taiwan 49 M     FU=1 year     
 Single           
Ramos-Levi et al 
2014 (41) 
Retrospective N=141 53 43.7±5.6 5 (2.0- 10.0) 
7.3 (6.5- 
8.4) 




 Spain 30 M:81 F     FU=1 year SG,    





 2006- 2011           
Cotillard et al 2015 
(42) 




 Single 15 M:45 F     FU=1 year     
Stallard et al 2016 
(43) 
Retrospective N=98 49.7±8.5 
49.7 (48.1-
51.1) 
6.7±6.6 7.6 (7.3-7.9) 






 Canada 22 M:76 F     FU=1 year SG    
 Single           
 01/01/11 – 06/14           
 
N = Total number of participants; n = Number of participants achieving diabetes remission; M = Male; F = Female; R = Remitters; NR = Non-
remitters; NI = Non-Insulin; I = Insulin; FU = Follow-up; V Dev = validated in internal/external cohort while model development stage; Ext V = 





Table 3: Study characteristics of validation studies 
Publication 
Reference 
Source of data Participant 
characteristics 




   Age BMI Diabetes 
Duration 
HbA1c    
Lee et al 2015 
modified (44) 
Retrospective N=85 41.9±10.9 39.0±7.4 2.7±3.1 8.1 ±1.7 n(CR+PR) =63/85 (74.1%) SG ABCD 
 Single F:M     FU=1 year   
 Taiwan         
 2006-2013         
Lee et al 2015 
(45) 
Retrospective N=157 35.7 39.8±8.0 NA 8.3 ±1.9 n=111 (77.1%) @1 year RYGB ABCD 
 Single 52 M:105 F     n=97 (71.3%) @5 years SG  
 Taiwan      FU=6 (5-8) years   
 2006-2009         
Lee et al 2015 
(46) 
Single N=80 out of 512 had 
BMI<30 
47.7±9.1 26.9±2.2 6.5±5.1 9.1±1.8 n(CR) =20 (25%) RYGB ABCD 
 Taiwan F=50 (62.5%)     FU=1 year SG  
 2007-2013         
Sampaio-Neto et 
al 2015 (47) 
Retrospective N=70 47.9±9.9 NA NA 7.6±1.8 n (CR+ PR)=42 (35+7) (60%) RYGB DiaRem 
 Single 6 M:64 F     FU=1 year   
 Brazil         
 2012-2013         
Lee et al 2016 
(48) 
Retrospective N=245 44.2±10.4 35.7±7.8 5.8±5.0 8.8±1.6 n=130 (53.1%) RYGB DiaRem 
 Single 95 M:150 F     FU=1 year  ABCD 
 Taiwan         
 2007-2013         
Lee et al 2017 
(49) 
Prospective N=579 (230 M:349 F)     n=361 (62.3%)/579 @1 year RYGB ABCD 
 Single 48 M:61 F (SG)     n=71 (49.7%)/143 @5 year SG  
 Taiwan 182 M:288 F (RYGB)        





  RYGB (N=470) 41.8±10.9 36.9±7.2 4.5±4.8 8.6±1.7    
Mehaffey et al 
2017 (50) 
Prospective N=57 75%F (2 years FU)     n@2 years =37(65%) RYGB DiaRem 
 USA N=31 55% F (10 years 
FU) 
    n@10 years=18(58%)   
 2004-2013 2 year FU 49.2 52.1 ±1.5 NA 8.3    
  10 year FU 45.8 48.0 ±6.6 NA 7.7    
Honarmand et al 
2017 (51) 
Retrospective N=900 51.0±9.1 49±8.07 NA 7.6±1.5 n=333 (37%) RYGB DiaRem 
 MC 667 F     FU=1 year   
 USA         
 2010-2015         
Tharakan et al 
2017 (52) 
Retrospective N=262 51±9.5 45.3±7.1 NA 8.2±1.8 n=85 (32.5%) RYGB DiaRem 
 Single 105 M:157 F     FU=1 year   
 UK         
 2007-2014         
Raj et al 2017 
(53) 
Prospective N=53 45.86±11.69 43.25±7.4 3 (range 0-40) 8.07±1.98 n=43 (81.1%) RYGB ABCD 
 Single 26 M:27 F     FU=1 year SG  
 India         
 2014-2015         
Seki et al 2018 
(54) 
Retrospective N=72 46.8±9.0 31.7±2.0 9.6±6.9 8.9±1.5 
 
n(CR)=22(31%) SG ABCD 
 Single 37 M:35 F     n(PR)=49%   
 Japan      FU=1 year   
 2007-2015         
Shen et al 2018 
(55) 
Retrospective N=128 42.4±10.6 39.2±5.8 3.2±3.8 8.0±1.7 n(CR)=92 (71.9%) SG ABCD 
 Taiwan 58 M:70 F     n(PR)=103 (80.5%)  IMS 
 2011-2016      FU=1 year  DiaRem 
         AdDiaRem 
         DiaBetter 
Naitoh et al 2018 
(56) 





 MC 140M:158 F     FU=1 year LSG/DJB  
 Japan LSG (N=177) 45.2 45.2 5.9±6.1 7.3±6.0    
 2005-2015 LSG/DJB (N=131) 45.2 43.5 7.7±1.7 8.3±1.7    
Ahuja et al 2018 
(57) 
Retrospective N=102 45.63±11.12 44.85±9.24 5.3±5.08 8.26±1.8 n=72 (70.6%) RYGB DiaRem 
 Single      FU=1 year  DRS 
 India        ABCD 
 2010-2015         
Almalki et al 
2018 (58) 
Retrospective N=406 42.6 36.4 3.1 8.6 n=291 (71.7%) RYGB ABCD 
 Single F=64%     FU=5 years   
 Taiwan         
 2007-2015         
Chen et al 2018 
(59) 
Single N=310 40.1±11.1 37.8±7.6 3.6±4.4 8.6±1.8 n=224 (72.3%) RYGB IMS 
 Taiwan 114 M:196 F     FU=5 years SG ABCD 
 2004-2012         
Wood et al 2018 
(60) 
Retrospective N=520 46.7 to 53 NA NA 7.2 to 7.5 n=249 RYGB DiaRem 
 Single 124 M:396 F     n=173 (RYGB) SG  
 USA      n=63 (SG) GB  
 2002-2014      n=13 (GB)   
Dicker et al 2019 
(61) 
Retrospective N=2190 47.1±10.9 43.5±6.3 NA 7.7±1.6 n=897 (59.7%)/1502 @ 2 years RYGB AdDiaRem 
 Israel 64.8% F     n=782 (53.6%)/1459 @ 5 years SG DiaRem 
 1999- 2011       GB  
Kam et al 2020 
(62) 
Retrospective N=214@1 year 48 (37-57) 30.6 (28.7-32.9) 6.0 (3-10) 8.0 (7.1-9.8) 113 of 214 (52.8%) @1 RYGB ABCD, 
 China 131@ 3 year     59 of 131 (45.0%) @ 3  DiaRem, 
  117 (54.7) F       AdDiaRem
, 
         DiaBetter 
Park 2020 (63) Retrospective N=135 40 ± 11 39.0 ± 6.3 1 (0-5) year 7.5 (6.8- 8.9) n= 88 (65.2%) RYGB IMS 





Lee et al 2020 
(64) 
Retrospective N=59 47.7± 12.4 37.6 ± 5.1 2.7 ±3.1 years 8.3± 2.2% 37 (62.7%) @ 1 year SG ABCD 
 2006- 2014 F     24 (42.4%) @ 5 year   
Guerron et al 
2020 (65) 
Retrospective N= 602 50.6 ±10.2 47.1 ±7.8 NA 7.5 ± 1.4 n (CR) = 215 (35.7%) RYGB, SG,  DiaRem 
 North Carolina 441 (73.3%) F     n (only PR) = 134 (22.3%) BPD/DS,   
 2000-2007       LAGB  
 
N = total number of participants; n = number of participants achieving diabetes remission; Single = single centre; M = male; F = female; MC = 
multi-centre; FU = follow-up; RYGB = gastric bypass; SG = sleeve gastrectomy; GB = gastric band; LSG = laparoscopic sleeve gastrectomy; 
LSG/DJB = LSG with duodenal-jejunal bypass. 
 
